Skip to main content

Low-to-Moderate Agreement Seen for Diagnosing Breast Cancer-Related Lymphedema

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 24, 2025.

via HealthDay

THURSDAY, April 24, 2025 -- Different measurement tools and diagnostic criteria show low-to-moderate agreement for diagnosing breast cancer-related lymphedema (BCRL), according to a study published in the April issue of Rehabilitation Oncology.

Cheryl L. Brunelle, P.T., from Massachusetts General Hospital in Boston, and colleagues examined diagnostic agreement among commonly utilized diagnostic thresholds for BCRL among 60 patients measured using four methods: tape measure (every 4 cm [Q4] and National Lymphedema Network [NLN] methods) converted to volume, optoelectronic limb volumetry, and bioimpedance spectroscopy (BIS). Relative volume change (RVC) ≥10 percent, absolute volume difference ≥10 percent, and L-Dex scores >6.5 or >10 with and without preoperative baseline were compared as diagnostic thresholds.

Data were analyzed from 57 participants; 36.8 percent were diagnosed with BCRL (RVC ≥10 percent). The researchers found that when BCRL diagnosis included preoperative baseline, poor and insignificant diagnostic agreement was seen between RVC ≥10 percent and L-Dex increase ≥6.5 (Cohen's kappa, −0.083). Fair diagnostic agreement was seen between diagnosis made with versus without incorporation of preoperative baseline measurement (with preoperative baseline RVC and BIS: Cohen's kappa, 0.233; without preoperative baseline NLN, Q4, volumeter, or BIS without baseline: Cohen's kappa, 0.308); moderate agreement was seen for diagnosis via RVC versus volumeter (Cohen's kappa, 0.531). No diagnostic agreement was seen between L-Dex increase ≥6.5 from baseline and measures without preoperative baseline (NLN, Q4, and volumeter) for the 21 patients with BIS baseline.

"Our findings highlight the unacceptably low levels of agreement between different tests for recognizing this complication, and the urgent need to establish standardized diagnostic criteria," Brunelle said in a statement.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

AI Support Improves Breast Cancer Detection Accuracy in Mammography

MONDAY, July 14, 2025 -- Artificial intelligence (AI) support improves radiologists' breast cancer detection accuracy when reading mammograms, according to a study published...

Varying Associations ID'd Between Hormone Therapy, Young-Onset Breast Cancer

THURSDAY, July 10, 2025 -- Associations between hormone therapy and young-onset breast cancer (diagnosed at younger than 55 years) vary, according to a study published online in...

Removing Out-of-Pocket Fee Boosts Rates of Digital Breast Mammography

WEDNESDAY, July 9, 2025 -- Removing a modest out-of-pocket fee significantly improves access to digital breast tomosynthesis (DBT; 3D mammography), particularly among underserved...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.